198 related articles for article (PubMed ID: 2985781)
1. A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.
Weishaar RE; Cain MH; Bristol JA
J Med Chem; 1985 May; 28(5):537-45. PubMed ID: 2985781
[TBL] [Abstract][Full Text] [Related]
2. The effect of cyclic AMP and cyclic GMP phosphodiesterase inhibitors on the superoxide burst of guinea-pig peritoneal macrophages.
Turner NC; Wood LJ; Burns FM; Gueremy T; Souness JE
Br J Pharmacol; 1993 Apr; 108(4):876-83. PubMed ID: 8387385
[TBL] [Abstract][Full Text] [Related]
3. Isoenzyme-selective cyclic nucleotide phosphodiesterase inhibitors: effects on airways smooth muscle.
Raeburn D; Advenier C
Int J Biochem Cell Biol; 1995 Jan; 27(1):29-37. PubMed ID: 7757880
[TBL] [Abstract][Full Text] [Related]
4. Multiple molecular forms of cyclic nucleotide phosphodiesterase in cardiac and smooth muscle and in platelets. Isolation, characterization, and effects of various reference phosphodiesterase inhibitors and cardiotonic agents.
Weishaar RE; Burrows SD; Kobylarz DC; Quade MM; Evans DB
Biochem Pharmacol; 1986 Mar; 35(5):787-800. PubMed ID: 3006691
[TBL] [Abstract][Full Text] [Related]
5. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents.
Marcoz P; Prigent AF; Lagarde M; Nemoz G
Mol Pharmacol; 1993 Nov; 44(5):1027-35. PubMed ID: 8246905
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors of cyclic nucleotide phosphodiesterase 3 and 5 as therapeutic agents in heart failure.
Stehlik J; Movsesian MA
Expert Opin Investig Drugs; 2006 Jul; 15(7):733-42. PubMed ID: 16787138
[TBL] [Abstract][Full Text] [Related]
7. Multiple molecular forms of phosphodiesterase and the regulation of cardiac muscle contractility.
Weishaar RE; Kobylarz-Singer DC; Quade MM; Steffen RP; Kaplan HR
J Cyclic Nucleotide Protein Phosphor Res; 1986-1987; 11(7):513-27. PubMed ID: 2831259
[TBL] [Abstract][Full Text] [Related]
8. Selective inhibitor of platelet cyclic adenosine monophosphate phosphodiesterase, cilostamide, inhibits platelet aggregation.
Hidaka H; Hayashi H; Kohri H; Kimura Y; Hosokawa T; Igawa T; Saitoh Y
J Pharmacol Exp Ther; 1979 Oct; 211(1):26-30. PubMed ID: 226672
[No Abstract] [Full Text] [Related]
9. Selective inhibition of cyclic AMP and cyclic GMP phosphodiesterases of cardiac nuclear fraction.
Ahluwalia GS; Rhoads AR
Biochem Pharmacol; 1982 Mar; 31(5):665-9. PubMed ID: 6177320
[TBL] [Abstract][Full Text] [Related]
10. Differential pharmacologic sensitivity of cyclic nucleotide phosphodiesterase isozymes isolated from cardiac muscle, arterial and airway smooth muscle.
Silver PJ; Hamel LT; Perrone MH; Bentley RG; Bushover CR; Evans DB
Eur J Pharmacol; 1988 May; 150(1-2):85-94. PubMed ID: 2841146
[TBL] [Abstract][Full Text] [Related]
11. Effects of divalent metals on the specificity of inhibitors of the cyclic nucleotide phosphodiesterases from bovine heart.
Donnelly TE; Barron B
Biochim Biophys Acta; 1981 Jan; 657(1):168-78. PubMed ID: 6260197
[TBL] [Abstract][Full Text] [Related]
12. Proteolysis of cyclic AMP phosphodiesterase-II attenuates its ability to be inhibited by compounds which exert positive inotropic actions in cardiac tissue.
Price B; Pyne NJ; Houslay MD
Biochem Pharmacol; 1987 Dec; 36(23):4047-54. PubMed ID: 2825712
[TBL] [Abstract][Full Text] [Related]
13. Resolution of soluble cyclic nucleotide phosphodiesterase isoenzymes, from liver and hepatocytes, identifies a novel IBMX-insensitive form.
Lavan BE; Lakey T; Houslay MD
Biochem Pharmacol; 1989 Nov; 38(22):4123-36. PubMed ID: 2480793
[TBL] [Abstract][Full Text] [Related]
14. Selective inhibition of separated forms of cyclic nucleotide phosphodiesterase from rat heart by some pentasubstituted quercetin analogs.
Picq M; Prigent AF; Nemoz G; Pacheco H
Biochem Pharmacol; 1982 Sep; 31(17):2777-82. PubMed ID: 6291544
[TBL] [Abstract][Full Text] [Related]
15. Effects of zaprinast and rolipram on platelet aggregation and arrhythmias following myocardial ischaemia and reperfusion in anaesthetized rabbits.
Holbrook M; Coker SJ
Br J Pharmacol; 1991 Aug; 103(4):1973-9. PubMed ID: 1655149
[TBL] [Abstract][Full Text] [Related]
16. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta.
Lugnier C; Schoeffter P; Le Bec A; Strouthou E; Stoclet JC
Biochem Pharmacol; 1986 May; 35(10):1743-51. PubMed ID: 2423089
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacologic value of cyclic nucleotide phosphodiesterase inhibitors].
Nemoz G; Prigent AF
Ann Pharm Fr; 1984; 42(2):99-112. PubMed ID: 6091520
[No Abstract] [Full Text] [Related]
18. Flavonoids are selective cyclic GMP phosphodiesterase inhibitors.
Ruckstuhl M; Beretz A; Anton R; Landry Y
Biochem Pharmacol; 1979; 28(4):535-8. PubMed ID: 218594
[No Abstract] [Full Text] [Related]
19. Selective inhibition of rat lung cyclic AMP phosphodiesterase and cyclic GMP phosphodiesterase by cyclic nucleotides and their analogues and various drugs [proceedings].
Butt NM; Saeed SA; Collier HO
Biochem Soc Trans; 1980 Jun; 8(3):380-1. PubMed ID: 6249674
[No Abstract] [Full Text] [Related]
20. Relationship between inhibition of cardiac muscle phosphodiesterases, changes in cyclic nucleotide levels, and contractile response for CI-914 and other novel cardiotonics.
Weishaar RE; Quade MM; Schenden JA; Evans DB
J Cyclic Nucleotide Protein Phosphor Res; 1985; 10(6):551-64. PubMed ID: 3003170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
